“Real-World” Breo Study: A Q&A With GSK’s David Leather

GlaxoSmithKline is evaluating its once-daily ICS/LABA Breo Ellipta in a “real-world” trial called the Salford Lung Study, with as little intervention from the clinical trial team as possible, to see how the product impacts health outcomes versus existing treatments. David Leather, MD, global medical affairs leader for GSK’s respiratory franchise, is heading the trial and talks about the trial design, challenges, and why the company launched the study in the first place.

GlaxoSmithKline PLC is hoping to use evidence from a “real-world” trial to convince payers that Breo Ellipta (fluticasone/vilanterol) is worth paying for. The aim is to collect data showing Breo, GSK’s new, once-daily inhaled corticosteroid/long-acting beta2 agonist (ICS/LABA) for chronic obstructive pulmonary disease (COPD) improves patient adherence compared with existing twice-daily ICS/LABA treatments and that as a result it improves health outcomes.

To support its case, in 2012, the company initiated an innovative clinical trial called the Salford Lung Study, testing with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By 

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.

Orphan Drug Trial Sponsors ‘Playing Catch-Up’ With Regulators – But Automation Can Help

 

Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.

More from R&D

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.

Future Of US FDA’s Diversity Action Plan Guidance ‘Up In The Air’ As Statutory Deadline Looms

 
• By 

A 26 June deadline looms for the final guidance even though a draft guidance was removed from the agency’s website to comply with President Trump’s gender ideology executive order. The concepts underpinning the guidance are still relevant, legal experts say.

Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding

 
• By 

Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.